The renal parenchyma evaluation: MAG3 vs. DMSA.
Scintigraphy with Tc-99m dimercaptosuccinic acid (DMSA) is considered a reference method for assessment of parenchymal lesions and estimation of differential kidney function. The aim of study was to evaluate Tc-99m mercaptoacetyltriglycine (MAG3) dynamic renal scintigraphy for the same purpose. 188 patients, submitted to both studies within three months, were divided in two groups. In the first, 83 DMSA images were compared to parenchymal phase of MAG3 scintigraphy. Kidney morphology was independently evaluated by four observers. In the second group (N = 105), differential function was calculated in MAG3 and DMSA studies and the respective results were compared. Findings corresponded completely in 85% of patients. There were no statistically significant differences between calculated differential function on DMSA and MAG3 images. The results showed that most of parenchymal lesions detected on DMSA scans can be identified on MAG3 parenchymal scans. Both studies can be equally used for the calculation of differential kidney function.
Smokvina
Aleksandar
A
Department of Nuclear Medicine, University Hospital Center Rijeka, Rijeka, Croatia. smokvina@medri.hr
Grbac-Ivanković
Svjetlana
S
Girotto
Neva
N
Dezulović
Mirna Subat
MS
Saina
Giordano
G
Barković
Marina Miletić
MM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000000981:diagnostic imaging*; D007677:Kidney Function Tests / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D016037:Single-Blind Method; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D017263:Technetium Tc 99m Mertiatide
D019275:Radiopharmaceuticals; D017263:Technetium Tc 99m Mertiatide; D019783:Technetium Tc 99m Dimercaptosuccinic Acid